In today’s briefing:
- Classys: One of Korea’s Top Beauty Medical Device Makers + Higher Shares Cancellation and Dividends
- Jazz Pharmaceuticals: Zanidatamab’s Future Progression & 4 Other Drivers
- Karuna Therapeutics: Is The Bidding Battle Underway?
- The Cooper Companies Inc.: Huge Potential Of Myopia Management Market As A Growth Catalyst! – Key Drivers
- Viatris Inc.: Strategic Expansion Into Key Therapeutic Verticals & 6 Other Major Drivers
- Veeva Systems Inc.: Expansion of the Data Cloud & 5 Other Factors Driving Growth! – Financial Forecasts
- Eisai Co Ltd (4523 JP): Despite Sluggish Launch, Ambitious Long-Term Target Set for Leqembi
Classys: One of Korea’s Top Beauty Medical Device Makers + Higher Shares Cancellation and Dividends
- Classys is one of the top beauty medical device companies in Korea. Classys’ main products include Shurink Universe and Volnewmer.
- We have a positive view of Classys (214150 KS). Classys is trading at relatively reasonable valuations, considering the company’s strong growth in sales and profits.
- On 28 February, Classys announced a shareholder return amount of 38 billion won (including share cancellation of about 25 billion won and dividend payout of 13 billion won).
Jazz Pharmaceuticals: Zanidatamab’s Future Progression & 4 Other Drivers
- Jazz Pharmaceuticals reported a strong financial year in 2023, with overall revenues surpassing $3.8 billion.
- This performance was primarily driven by the growth of key products in the company’s portfolio – Xywav, Epidiolex and Rylaze, which collectively accounted for a 27% year-over-year increase in revenue.
- The company’s sleep therapeutic area contributed more than $1.9 billion in annual revenue, indicating a strong demand for its offerings given the high prevalence of sleep related disorders.
Karuna Therapeutics: Is The Bidding Battle Underway?
- In December 2023, American multinational pharmaceutical company Bristol Myers Squibb has agreed to acquire Karuna Therapeutics for $330 per share in cash, implying a total equity value of $14B.
- The special meeting of Karuna’s shareholders to be held on March 12, 2023, to consider and vote on various proposals necessary to approve upcoming M&A deal.
- I expect the bidding battle among big pharma to acquire Karuna Therapeutics and its valuable pipeline of transformative medicines to treat schizophrenia and psychosis in Alzheimer’s disease.
The Cooper Companies Inc.: Huge Potential Of Myopia Management Market As A Growth Catalyst! – Key Drivers
- As per the Q1 2024 Cooper Companies earnings, the company reported an outstanding start to the fiscal year with record quarterly revenues of $932 million.
- CooperVision rolled in solid growth worldwide, while CooperSurgical recorded its 13th consecutive quarter of double-digit organic growth.
- The firm’s earnings were equally strong, with capacity expansion progressing well and demand remaining healthy globally.
Viatris Inc.: Strategic Expansion Into Key Therapeutic Verticals & 6 Other Major Drivers
- Viatris Inc.
- reported its Q4 and Full Year 2023 Earnings with strong operational results, showing revenue growth for the third consecutive quarter.
- As Viatris begins 2024, it continues to generate strong free cash flows that provide the flexibility to balance capital return to shareholders and strategic investments for future growth.
Veeva Systems Inc.: Expansion of the Data Cloud & 5 Other Factors Driving Growth! – Financial Forecasts
- Veeva Systems posted robust results for its Q4 and Fiscal 2024 year during its earnings call.
- Revenues for the quarter totalled $631 million and for the year they were $2.4 billion, both exceeding guidance.
- Non GAAP operating income surpassed expectations too, with $239 million for Q4 and $843 million for the full year.
Eisai Co Ltd (4523 JP): Despite Sluggish Launch, Ambitious Long-Term Target Set for Leqembi
- Eisai Co Ltd (4523 JP) has come out with ambitious revenue target for Alzheimer’s disease drug Leqembi with new estimates for global eligible patient population and potential indication expansions.
- By FY27, Eisai expects Leqembi can generate revenue of ¥290B (~$2B) worldwide. Leqembi revenue can potentially ballooned to a whopping ¥1.6T (~$10.8B) by FY33, according to the company.
- Through January, Eisai could reach just 2,000 patients in the U.S. versus target of 10K patients by March. The sluggish progress of Leqembi makes Eisai’s target difficult to achieve.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
